Clinical Trial Update: Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity [NA]

View source ↗

Summary

A completed clinical trial evaluating L-tetrahydropalmatine (l-THP), a dopamine antagonist with anti-inflammatory and antiprotozoal activity, for schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• L-tetrahydropalmatine (L-tetrahydropalmatine)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Schizophrenia | NA | Status: COMPLETED | Results posted: 2020-04-07